BMEA241115C17500
- 0.34
- 0.000.00%
Biomea Fusion Newsroom
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $40
Buy Recommendation for Biomea Fusion: Promising Clinical Developments of Icovamenib in Diabetes Treatment
Express News | Biomea Fusion Announces Approval of “Icovamenib” as International Nonproprietary Name for Bmf-219
Biomea Fusion To Host Conference Call And Webcast On Wednesday, October 30 At 4:30 Pm ET To Announce Lead Clinical Candidate, BMF-650, A Oral Small-Molecule GLP-1 Receptor Agonist And Preclinical Data Combining BMF-219 With A GLP-1 RA-Based Therapy
Arcadium Lithium, Norwegian Cruise Line, GitLab, Chewy And Other Big Stocks Moving Higher On Wednesday
EF Hutton Initiates Coverage On Biomea Fusion With Buy Rating, Announces Price Target of $128
Biomea Fusion Analyst Ratings
Biomea Fusion To Present Data From The Company's COVALENT-111 and COVALENT-112 Diabetes Clinical Trials Will Be Featured During A Long Oral Presentation And Two Short Oral Presentations At The 1st Asian Conference On Innovative Therapies For Diabetes...
Independent Director of Biomea Fusion Michael J. Hitchcock Buys 200% More Shares
Express News | Biomea Announces Formation of Global Scientific Advisory Board With 22 World-Renowned Diabetes Experts
IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Deliver On Growth Plans?
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $10
Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Raises Target Price to $41
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $10 to $60
Biomea Upgraded by Analysts After FDA Lifts Clinical Hold
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate
Biomea Fusion's FDA Hold Seen as Possible Blessing in Disguise -- Market Talk
Biomea Fusion Is Maintained at Equal-Weight by Barclays
Truist Securities Upgrades Biomea Fusion to Buy, Maintains Price Target to $54